Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8528262 | Clinical Therapeutics | 2018 | 15 Pages |
Abstract
Andecaliximab administered as 3 infusions over 29 days was generally safe and well tolerated in patients with RA. The majority of total plasma MMP9 was bound by andecaliximab after the first administration. Clinical studies of increased treatment duration in larger patient cohorts are warranted. ClinicalTrials.gov identifier: NCT02176876. Registered on 25 June 2014.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
David L. MD, MBA, Blanka MD, Sophe BS, Hao PhD, MS, Yan PhD, Preeti PhD, Guang PhD, Victoria PhD, John S. MD, PhD,